Skip to main content
main-content

Tipp

Weitere Artikel dieser Ausgabe durch Wischen aufrufen

Erschienen in: Wiener Medizinische Wochenschrift 15-16/2013

01.08.2013 | main topic

Advanced basal cell carcinoma

verfasst von: MD Uwe Wollina, MD, PhD Georgi Tchernev

Erschienen in: Wiener Medizinische Wochenschrift | Ausgabe 15-16/2013

Einloggen, um Zugang zu erhalten
share
TEILEN

Summary

Basal cell carcinoma (BCC) is the most common skin malignancy worldwide. Ultraviolet light exposure is the best known exogenous factor in BCC development. This is also the target for primary prevention. Advanced BCC include locally advanced tumors and metastatic tumors. Prognosis is worse compared to stage I and II BCCs. Mohs or micrographically controlled surgery is the gold standard of treatment. In patients with tumors that cannot be completely removed radiotherapy was the only alternative in the past. More recently new drugs for targeted therapy of signaling pathways like sonic hedgehog or epidermal growth factor receptor became available. More small molecules are under investigation. Since the complete response rates are limited, future research has to evaluate their combination with surgery.
Literatur
1.
Zurück zum Zitat Lomas A, Leonardi-Bee J, Bath-Hextall F. A systematic review of worldwide incidence of nonmelanoma skin cancer. Br J Dermatol. 2012;166:1069–80. PubMedCrossRef Lomas A, Leonardi-Bee J, Bath-Hextall F. A systematic review of worldwide incidence of nonmelanoma skin cancer. Br J Dermatol. 2012;166:1069–80. PubMedCrossRef
2.
Zurück zum Zitat Fartasch M, Diepgen TL, Schmitt J, Drexsler H. The relationship between occupational sun exposure and nonmelanoma skin cancer. Dtsch Ärztebl Int. 2012;109:715–20. PubMed Fartasch M, Diepgen TL, Schmitt J, Drexsler H. The relationship between occupational sun exposure and nonmelanoma skin cancer. Dtsch Ärztebl Int. 2012;109:715–20. PubMed
3.
Zurück zum Zitat Wollina U. Nonmelanoma skin cancer on the rise. J Cutan Aesthet Surg. 2012;5:11. PubMed Wollina U. Nonmelanoma skin cancer on the rise. J Cutan Aesthet Surg. 2012;5:11. PubMed
4.
Zurück zum Zitat Chinem VP, Mior HA. Epidemiology of basal cell carcinoma. An Bras Dermatol. 2011;86:292–305. PubMedCrossRef Chinem VP, Mior HA. Epidemiology of basal cell carcinoma. An Bras Dermatol. 2011;86:292–305. PubMedCrossRef
5.
Zurück zum Zitat Adinarayan M, Krishnamurthy SP. Clinicopathological evaluation of nonmelanoma skin cancer. Indian J Dermatol. 2011;56:670–2. PubMedCrossRef Adinarayan M, Krishnamurthy SP. Clinicopathological evaluation of nonmelanoma skin cancer. Indian J Dermatol. 2011;56:670–2. PubMedCrossRef
6.
Zurück zum Zitat Chang JM, Gao XM. Clinical and histopathological characteristics of basal cell carcinoma in Chinese patients. Chin Med J (Engl). 2013;126:211–4. PubMed Chang JM, Gao XM. Clinical and histopathological characteristics of basal cell carcinoma in Chinese patients. Chin Med J (Engl). 2013;126:211–4. PubMed
7.
Zurück zum Zitat Moser S, Borm J, Michic-Probst D, Jacobsen C, Kruse-Gujer AL. Metastatic basal cell carcinoma: report of a case and review of the literature. Oral Surg Oral Med Oral Pathol Oral Radiol. 2013. doi:pii:S2212-4403(12)00398-7. Moser S, Borm J, Michic-Probst D, Jacobsen C, Kruse-Gujer AL. Metastatic basal cell carcinoma: report of a case and review of the literature. Oral Surg Oral Med Oral Pathol Oral Radiol. 2013. doi:pii:S2212-4403(12)00398-7.
8.
Zurück zum Zitat Greinert R, Boniol M. Skin cancer—primary and secondary prevention (information campaigns and screening)—with a focus on children & sunbeds. Progr Biophys Mol Biol. 2011;107:473–6. CrossRef Greinert R, Boniol M. Skin cancer—primary and secondary prevention (information campaigns and screening)—with a focus on children & sunbeds. Progr Biophys Mol Biol. 2011;107:473–6. CrossRef
9.
Zurück zum Zitat Wollina U. Addiction to tanning—a new cause of early onset of nonmelanoma skin cancer. Open Dermatol J. 2009;3:144–9. CrossRef Wollina U. Addiction to tanning—a new cause of early onset of nonmelanoma skin cancer. Open Dermatol J. 2009;3:144–9. CrossRef
10.
Zurück zum Zitat Göppner D, Leverkus M. Basal cell carcinoma: from the molecular understanding of the pathogenesis to targeted therapy of progressive disease. J Skin Cancer. 2011;2011:650258. PubMed Göppner D, Leverkus M. Basal cell carcinoma: from the molecular understanding of the pathogenesis to targeted therapy of progressive disease. J Skin Cancer. 2011;2011:650258. PubMed
11.
Zurück zum Zitat Parren LJ, Frank J. Hereditary tumour syndromes featuring basal cell carcinomas. Br J Dermatol 2011;165:30–4. PubMedCrossRef Parren LJ, Frank J. Hereditary tumour syndromes featuring basal cell carcinomas. Br J Dermatol 2011;165:30–4. PubMedCrossRef
12.
Zurück zum Zitat de Vries E, Arnold M, Altsitsiadis E, Trakatelli M, Hinrichs B, Stockfleth E, et al. Potential impact of interventions resulting in reduced exposure to ultraviolet (UV) radiation (UVA and UVB) on skin cancer incidence in four European countries, 2010–2050. Br J Dermatol. 2012;167(Suppl 2):53–62. PubMedCrossRef de Vries E, Arnold M, Altsitsiadis E, Trakatelli M, Hinrichs B, Stockfleth E, et al. Potential impact of interventions resulting in reduced exposure to ultraviolet (UV) radiation (UVA and UVB) on skin cancer incidence in four European countries, 2010–2050. Br J Dermatol. 2012;167(Suppl 2):53–62. PubMedCrossRef
13.
Zurück zum Zitat Burnett ME, Wang SQ. Current sunscreen controversies: a critical review. Photodermatol Photoimmunol Photomed. 2011;27:58–67. PubMedCrossRef Burnett ME, Wang SQ. Current sunscreen controversies: a critical review. Photodermatol Photoimmunol Photomed. 2011;27:58–67. PubMedCrossRef
14.
Zurück zum Zitat Weinstock MA, Bingham SF, Digiovanna JJ, Rizzo AE, Marcolivio K, Hall R, et al. Tretinoin and the prevention of keratinocyte carcinoma (basal and squamous cell carcinoma of the skin): a veterans affairs randomized chemoprevention trial. J Invest Dermatol. 2012;132:1583–90. PubMedCrossRef Weinstock MA, Bingham SF, Digiovanna JJ, Rizzo AE, Marcolivio K, Hall R, et al. Tretinoin and the prevention of keratinocyte carcinoma (basal and squamous cell carcinoma of the skin): a veterans affairs randomized chemoprevention trial. J Invest Dermatol. 2012;132:1583–90. PubMedCrossRef
15.
Zurück zum Zitat Lien MH, Fenske NA, Glass LF. Advances in the chemoprevention of nonmelanoma skin cancer in high-risk organ transplant recipients. Semin Oncol. 2012;39:134–8. PubMedCrossRef Lien MH, Fenske NA, Glass LF. Advances in the chemoprevention of nonmelanoma skin cancer in high-risk organ transplant recipients. Semin Oncol. 2012;39:134–8. PubMedCrossRef
16.
Zurück zum Zitat Elmets CA, Viner JL, Pentland AP, Cantrell W, Lin HY, Bailey H, et al. Chemoprevention of nonmelanoma skin cancer with celecoxib: a randomized, double-blind, placebo-controlled trial. J Natl Cancer Inst. 2010;102:1835–44. PubMedCrossRef Elmets CA, Viner JL, Pentland AP, Cantrell W, Lin HY, Bailey H, et al. Chemoprevention of nonmelanoma skin cancer with celecoxib: a randomized, double-blind, placebo-controlled trial. J Natl Cancer Inst. 2010;102:1835–44. PubMedCrossRef
17.
Zurück zum Zitat Kasper M, Jaks V, Hohl D, Toftgård R. Basal cell carcinoma—molecular biology and potential new therapies. J Clin Invest. 2012;122:455–63. PubMedCrossRef Kasper M, Jaks V, Hohl D, Toftgård R. Basal cell carcinoma—molecular biology and potential new therapies. J Clin Invest. 2012;122:455–63. PubMedCrossRef
18.
Zurück zum Zitat Mancuso M, Leonardi S, Tanori M, Pasquali E, Pierdomenico M, Rebessi S, et al. Hair cycle dependent basal cell carcinoma tumorigenesis in Ptc1neo67/+mice exposed to radiation. Cancer Res. 2006;66:6606–14. PubMedCrossRef Mancuso M, Leonardi S, Tanori M, Pasquali E, Pierdomenico M, Rebessi S, et al. Hair cycle dependent basal cell carcinoma tumorigenesis in Ptc1neo67/+mice exposed to radiation. Cancer Res. 2006;66:6606–14. PubMedCrossRef
19.
Zurück zum Zitat Raasch BA, Buettner PG, Garbe C. Basal cell carcinoma: histological classification and body-site distribution. Br J Dermatol. 2006;155:401–7. PubMedCrossRef Raasch BA, Buettner PG, Garbe C. Basal cell carcinoma: histological classification and body-site distribution. Br J Dermatol. 2006;155:401–7. PubMedCrossRef
20.
Zurück zum Zitat Ad Hoc Task Force, Connolly SM, Baker DR, Coldiron BM, Fazio MJ, Storrs PA, et al. AAD/ACMS/ASDSA/ASMS 2012 appropriate use criteria for Mohs micrographic surgery: a report of the American Academy of Dermatology, American College of Mohs Surgery, American Society for Dermatologic Surgery Association, and the American Society for Mohs Surgery. J Am Acad Dermatol. 2012;67:531–50. PubMedCrossRef Ad Hoc Task Force, Connolly SM, Baker DR, Coldiron BM, Fazio MJ, Storrs PA, et al. AAD/ACMS/ASDSA/ASMS 2012 appropriate use criteria for Mohs micrographic surgery: a report of the American Academy of Dermatology, American College of Mohs Surgery, American Society for Dermatologic Surgery Association, and the American Society for Mohs Surgery. J Am Acad Dermatol. 2012;67:531–50. PubMedCrossRef
21.
Zurück zum Zitat Narayanan K, Hadid OH, Barnes EA. Mohs micrographic surgery versus surgical excision for periocular basal cell carcinoma. Cochrane Database Syst Rev. 2012;2:CD007041. PubMed Narayanan K, Hadid OH, Barnes EA. Mohs micrographic surgery versus surgical excision for periocular basal cell carcinoma. Cochrane Database Syst Rev. 2012;2:CD007041. PubMed
22.
Zurück zum Zitat Mendenhall WM, Amdur RJ, Hinerman RW, Cognetta AB, Mendenhall NP. Radiotherapy for cutaneous squamous and basal cell carcinomas of the head and neck. Laryngoscope. 2009;119:1994–9. PubMedCrossRef Mendenhall WM, Amdur RJ, Hinerman RW, Cognetta AB, Mendenhall NP. Radiotherapy for cutaneous squamous and basal cell carcinomas of the head and neck. Laryngoscope. 2009;119:1994–9. PubMedCrossRef
23.
Zurück zum Zitat Skiveren J, Mikkelsen MR, Daugberg H, Wulf HC. Skin reactions and quality of life after X-ray therapy of basal cell carcinoma. J Skin Cancer. 2012:825095. Skiveren J, Mikkelsen MR, Daugberg H, Wulf HC. Skin reactions and quality of life after X-ray therapy of basal cell carcinoma. J Skin Cancer. 2012:825095.
24.
Zurück zum Zitat Wollina U, Schreiber A, Merla K, Haroske G. Combined cetuximab and volumetric arc-radiotherapy in advanced recurrent squamous cell carcinoma of the scalp. Dermatol Rep. 2011;3:e 57. CrossRef Wollina U, Schreiber A, Merla K, Haroske G. Combined cetuximab and volumetric arc-radiotherapy in advanced recurrent squamous cell carcinoma of the scalp. Dermatol Rep. 2011;3:e 57. CrossRef
25.
Zurück zum Zitat Bianchi L, Orlandi A, Campione E, Angeloni C, Costanzo A, Spagnoli LG, Chimenti S. Topical treatment of basal cell carcinoma with tazarotene: a clinicopathological study on a large series of cases. Br J Dermatol. 2004;151:148–56. PubMedCrossRef Bianchi L, Orlandi A, Campione E, Angeloni C, Costanzo A, Spagnoli LG, Chimenti S. Topical treatment of basal cell carcinoma with tazarotene: a clinicopathological study on a large series of cases. Br J Dermatol. 2004;151:148–56. PubMedCrossRef
26.
Zurück zum Zitat Gaitanis G, Alexopoulos EC, Bassukas ID. Cryosurgery is more effective in the treatment of primary, nonsuperficial basal cell carcinomas when applied during and not prior to a five week imiquimod course: a randomized, prospective, open-label study. Eur J Dermatol. 2011;21:952–8. PubMed Gaitanis G, Alexopoulos EC, Bassukas ID. Cryosurgery is more effective in the treatment of primary, nonsuperficial basal cell carcinomas when applied during and not prior to a five week imiquimod course: a randomized, prospective, open-label study. Eur J Dermatol. 2011;21:952–8. PubMed
27.
Zurück zum Zitat Konnikov N, Avram M, Jarell A, Tannous Z. Pulsed dye laser as a novel nonsurgical treatment for basal cell carcinomas: response and follow up 12–21 months after treatment. Lasers Surg Med. 2011;43:72–8. PubMedCrossRef Konnikov N, Avram M, Jarell A, Tannous Z. Pulsed dye laser as a novel nonsurgical treatment for basal cell carcinomas: response and follow up 12–21 months after treatment. Lasers Surg Med. 2011;43:72–8. PubMedCrossRef
28.
Zurück zum Zitat Lawrence CM, Haniffa M, Dahl MG. Formalin-fixed tissue Mohs surgery (slow Mohs) for basal cell carcinoma: five-year follow-up data. Br J Dermatol. 2009;160:573–80. PubMedCrossRef Lawrence CM, Haniffa M, Dahl MG. Formalin-fixed tissue Mohs surgery (slow Mohs) for basal cell carcinoma: five-year follow-up data. Br J Dermatol. 2009;160:573–80. PubMedCrossRef
29.
Zurück zum Zitat Mosterd K, Krekels GA, Nieman FH, Ostertag JU, Essers BA, Dirksen CD, et al. Surgical excision versus Mohs ‘micrographic surgery for primary and recurrent basal cell carcinoma of the face: a prospective randomized controlled trial with five-years’ follow-up. Lancet Oncol. 2008;9:1149–56. PubMedCrossRef Mosterd K, Krekels GA, Nieman FH, Ostertag JU, Essers BA, Dirksen CD, et al. Surgical excision versus Mohs ‘micrographic surgery for primary and recurrent basal cell carcinoma of the face: a prospective randomized controlled trial with five-years’ follow-up. Lancet Oncol. 2008;9:1149–56. PubMedCrossRef
30.
Zurück zum Zitat Smeets NW, Krekels GA, Ostertag JU, Essers BA, Dirksen CD, Nieman FH, et al. Surgical excision vs Mohs’ micrographic surgery for basal cell carcinoma of the face: randomized controlled trial. Lancet. 2004;364:1766–72. PubMedCrossRef Smeets NW, Krekels GA, Ostertag JU, Essers BA, Dirksen CD, Nieman FH, et al. Surgical excision vs Mohs’ micrographic surgery for basal cell carcinoma of the face: randomized controlled trial. Lancet. 2004;364:1766–72. PubMedCrossRef
31.
Zurück zum Zitat Daudén E; BASALE Study Group. Effectiveness and satisfaction with imiquimod for the treatment of superficial basal cell carcinoma in daily dermatological practice. J Eur Acad Dermatol Venereol. 2011;25:1304–10. PubMedCrossRef Daudén E; BASALE Study Group. Effectiveness and satisfaction with imiquimod for the treatment of superficial basal cell carcinoma in daily dermatological practice. J Eur Acad Dermatol Venereol. 2011;25:1304–10. PubMedCrossRef
32.
Zurück zum Zitat Schulze HJ, Cribier B, Requena L, Reifenberger J, Ferrándiz C, Garcia Diez A, et al. Imiquimod 5 % cream for the treatment of superficial basal cell carcinoma: results from a randomized vehicle controlled phase III study in Europe. Br J Dermatol. 2005;152:939–47. PubMedCrossRef Schulze HJ, Cribier B, Requena L, Reifenberger J, Ferrándiz C, Garcia Diez A, et al. Imiquimod 5 % cream for the treatment of superficial basal cell carcinoma: results from a randomized vehicle controlled phase III study in Europe. Br J Dermatol. 2005;152:939–47. PubMedCrossRef
33.
Zurück zum Zitat Geisse J, Caro I, Lindholm J, Golitz L, Stampone P, Owens M. Imiquimod 5 % cream for the treatment of superficial basal cell carcinoma: results from two phase III, randomized, vehicle controlled studies. J Am Acad Dermatol. 2004;50:722–33. PubMedCrossRef Geisse J, Caro I, Lindholm J, Golitz L, Stampone P, Owens M. Imiquimod 5 % cream for the treatment of superficial basal cell carcinoma: results from two phase III, randomized, vehicle controlled studies. J Am Acad Dermatol. 2004;50:722–33. PubMedCrossRef
34.
Zurück zum Zitat Love WE, Bernhard JD, Bordeaux JS. Topical imiquimod or fluorouracil therapy for basal and squamous cell carcinoma: a systematic review. Arch Dermatol. 2009;145:1431–8. PubMedCrossRef Love WE, Bernhard JD, Bordeaux JS. Topical imiquimod or fluorouracil therapy for basal and squamous cell carcinoma: a systematic review. Arch Dermatol. 2009;145:1431–8. PubMedCrossRef
35.
Zurück zum Zitat Punjabi S, Cook LJ, Kersey P, Marks R, Cerio R. Solasodine glycoalkaloids: a novel topical therapy for basal cell carcinoma. A double-blind, randomized, placebo controlled, parallel group, multicenter study. Int J Dermatol. 2008;47:78–82. PubMedCrossRef Punjabi S, Cook LJ, Kersey P, Marks R, Cerio R. Solasodine glycoalkaloids: a novel topical therapy for basal cell carcinoma. A double-blind, randomized, placebo controlled, parallel group, multicenter study. Int J Dermatol. 2008;47:78–82. PubMedCrossRef
36.
Zurück zum Zitat Kowalzick L, Rogozinski T, Wimheuer R, Pilz J, Manske U, Scholz A, et al. Intralesional recombinant interferon beta-1a in the treatment of basal cell carcinoma: results of an open-label multicentre study. Eur J Dermatol. 2002;12:558–61. PubMed Kowalzick L, Rogozinski T, Wimheuer R, Pilz J, Manske U, Scholz A, et al. Intralesional recombinant interferon beta-1a in the treatment of basal cell carcinoma: results of an open-label multicentre study. Eur J Dermatol. 2002;12:558–61. PubMed
37.
Zurück zum Zitat Smucler R, Vlk M. Combination of Er:YAG laser and photodynamic therapy in the treatment of nodular basal cell carcinoma. Lasers Surg Med. 2008;40:153–8. PubMedCrossRef Smucler R, Vlk M. Combination of Er:YAG laser and photodynamic therapy in the treatment of nodular basal cell carcinoma. Lasers Surg Med. 2008;40:153–8. PubMedCrossRef
38.
Zurück zum Zitat Souza CS, Felicio LB, Ferreira J, Kurachi C, Bentley MV, Tedesco AC, et al. Long-term follow-up of topical 5-aminolaevulinic acid photodynamic therapy diode laser single session for nonmelanoma skin cancer. Photodiagnosis Photodyn Ther. 2009;6:207–13. PubMedCrossRef Souza CS, Felicio LB, Ferreira J, Kurachi C, Bentley MV, Tedesco AC, et al. Long-term follow-up of topical 5-aminolaevulinic acid photodynamic therapy diode laser single session for nonmelanoma skin cancer. Photodiagnosis Photodyn Ther. 2009;6:207–13. PubMedCrossRef
39.
Zurück zum Zitat Osiecka B, Jurczyszyn K, Ziółkowski P. The application of Levulan-based photodynamic therapy with imiquimod in the treatment of recurrent basal cell carcinoma. Med Sci Monit. 2012;18:I5–9. CrossRef Osiecka B, Jurczyszyn K, Ziółkowski P. The application of Levulan-based photodynamic therapy with imiquimod in the treatment of recurrent basal cell carcinoma. Med Sci Monit. 2012;18:I5–9. CrossRef
40.
Zurück zum Zitat Varga E, Korom I, Raskó E, Kis E, Varga J, Oláh J, et al. Neglected basal cell carcinomas in the twenty first century. J Skin Cancer. 2011;2011:392151. PubMed Varga E, Korom I, Raskó E, Kis E, Varga J, Oláh J, et al. Neglected basal cell carcinomas in the twenty first century. J Skin Cancer. 2011;2011:392151. PubMed
41.
Zurück zum Zitat Wollina U, Pabst F, Krönert C, Schorcht J, Haroske G, Klemm E, et al. High-risk basal cell carcinoma: an update. Expert Rev Dermatol. 2010;5:357–68. CrossRef Wollina U, Pabst F, Krönert C, Schorcht J, Haroske G, Klemm E, et al. High-risk basal cell carcinoma: an update. Expert Rev Dermatol. 2010;5:357–68. CrossRef
42.
Zurück zum Zitat Wollina U, Helm C, Schreiber A, Brandl H-G. Extensive cranial infiltration by basal cell carcinoma. J Cutan Med Surg. 2006;10:257–8. PubMed Wollina U, Helm C, Schreiber A, Brandl H-G. Extensive cranial infiltration by basal cell carcinoma. J Cutan Med Surg. 2006;10:257–8. PubMed
43.
Zurück zum Zitat Archontaki M, Stavrianos SD, Korkolis DP, Arnogiannaki N, Vassiliadis V, Liapakis IE, et al. Giant Basal cell carcinoma: clinicopathological analysis of 51 cases and review of the literature. Anticancer Res. 2009;29:2655–63. PubMed Archontaki M, Stavrianos SD, Korkolis DP, Arnogiannaki N, Vassiliadis V, Liapakis IE, et al. Giant Basal cell carcinoma: clinicopathological analysis of 51 cases and review of the literature. Anticancer Res. 2009;29:2655–63. PubMed
44.
Zurück zum Zitat Wollina U, Bayyoud Y, Krönert C, Nowak A. Giant epithelial malignancies (Basal cell carcinoma, squamous cell carcinoma): a series of 20 tumors from a single center. J Cutan Aesthet Surg. 2012;5:12–9. PubMedCrossRef Wollina U, Bayyoud Y, Krönert C, Nowak A. Giant epithelial malignancies (Basal cell carcinoma, squamous cell carcinoma): a series of 20 tumors from a single center. J Cutan Aesthet Surg. 2012;5:12–9. PubMedCrossRef
45.
Zurück zum Zitat Lackey PL, Sargent LA, Wong L, Brzezienski M, Kennedy JW. Giant basal cell carcinoma surgical management and reconstructive challenges. Ann Plast Surg. 2007;58:250–4. PubMedCrossRef Lackey PL, Sargent LA, Wong L, Brzezienski M, Kennedy JW. Giant basal cell carcinoma surgical management and reconstructive challenges. Ann Plast Surg. 2007;58:250–4. PubMedCrossRef
46.
Zurück zum Zitat Leibovitch I, McNab A, Sullivan T, Davis G, Selva D. Orbital invasion by periocular basal cell carcinoma. Ophthalmology. 2005;112:717–23. PubMedCrossRef Leibovitch I, McNab A, Sullivan T, Davis G, Selva D. Orbital invasion by periocular basal cell carcinoma. Ophthalmology. 2005;112:717–23. PubMedCrossRef
47.
Zurück zum Zitat Kleydman Y, Manolidis S, Ratner D. Basal cell carcinoma with intracranial invasion. J Am Acad Dermatol. 2009;60:1045–9. PubMedCrossRef Kleydman Y, Manolidis S, Ratner D. Basal cell carcinoma with intracranial invasion. J Am Acad Dermatol. 2009;60:1045–9. PubMedCrossRef
48.
Zurück zum Zitat Guthrie TH Jr, Porubsky ES, Luxenberg MN, Shah KJ, Wurtz KL, Watson PR. Cisplatin based chemotherapy in advanced basal and squamous cell carcinomas of the skin: results in 28 patients including 13 patients receiving multimodality therapy. J Clin Oncol. 1990;8:342–6. PubMed Guthrie TH Jr, Porubsky ES, Luxenberg MN, Shah KJ, Wurtz KL, Watson PR. Cisplatin based chemotherapy in advanced basal and squamous cell carcinomas of the skin: results in 28 patients including 13 patients receiving multimodality therapy. J Clin Oncol. 1990;8:342–6. PubMed
49.
Zurück zum Zitat Anasagasti-Angulo L, Garcia-Vega Y, Barcelona-Perez S, Lopez-Saura P, Bello-Rivero I. Treatment of advanced, recurrent, resistant to previous treatments basal and squamous cell skin carcinomas with a synergistic formulation of interferons. Open, prospective study. BMC Cancer. 2009;9:262. PubMedCrossRef Anasagasti-Angulo L, Garcia-Vega Y, Barcelona-Perez S, Lopez-Saura P, Bello-Rivero I. Treatment of advanced, recurrent, resistant to previous treatments basal and squamous cell skin carcinomas with a synergistic formulation of interferons. Open, prospective study. BMC Cancer. 2009;9:262. PubMedCrossRef
50.
Zurück zum Zitat Mevio N, Bertino G, Occhini A, Scelsi D, Tagliabue M, Mura F, Benazzo M. Electrochemotherapy for the treatment of recurrent head and neck cancers: preliminary results. Tumori. 2012;98:308–13. PubMed Mevio N, Bertino G, Occhini A, Scelsi D, Tagliabue M, Mura F, Benazzo M. Electrochemotherapy for the treatment of recurrent head and neck cancers: preliminary results. Tumori. 2012;98:308–13. PubMed
51.
Zurück zum Zitat Wollina U, Hansel G, Koch A, Köstler E. Oral capecitabine plus subcutaneous interferon alpha in advanced squamous cell carcinoma of the skin. J Cancer Res Clin Oncol. 2005;131:300–4. PubMedCrossRef Wollina U, Hansel G, Koch A, Köstler E. Oral capecitabine plus subcutaneous interferon alpha in advanced squamous cell carcinoma of the skin. J Cancer Res Clin Oncol. 2005;131:300–4. PubMedCrossRef
52.
53.
Zurück zum Zitat Kalapurakal SJ, Malone J, Robbins KT, Buescher L, Godwin J, Rao K. Cetuximab in refractory skin cancer treatment. J Cancer. 2012;3:257–61. PubMedCrossRef Kalapurakal SJ, Malone J, Robbins KT, Buescher L, Godwin J, Rao K. Cetuximab in refractory skin cancer treatment. J Cancer. 2012;3:257–61. PubMedCrossRef
54.
Zurück zum Zitat Caron J, Dereure O, Kerob D, Lebbe C, Guillot B. Metastatic basal cell carcinoma: report of two cases treated with cetuximab. Br J Dermatol. 2009;161:702–3. PubMedCrossRef Caron J, Dereure O, Kerob D, Lebbe C, Guillot B. Metastatic basal cell carcinoma: report of two cases treated with cetuximab. Br J Dermatol. 2009;161:702–3. PubMedCrossRef
55.
Zurück zum Zitat Müller H, Eisendle K, Gastl G, Höpfl R, Zelger B. Palliative therapy of giant basal cell carcinoma with the monoclonal antiepidermal growth factor receptor antibody cetuximab. Br J Dermatol. 2008;158:1386–8. PubMedCrossRef Müller H, Eisendle K, Gastl G, Höpfl R, Zelger B. Palliative therapy of giant basal cell carcinoma with the monoclonal antiepidermal growth factor receptor antibody cetuximab. Br J Dermatol. 2008;158:1386–8. PubMedCrossRef
56.
Zurück zum Zitat Von Hoff DD, LoRusso PM, Rudin CM, Reddy JC, Yauch RL, Tibes R, et al. Inhibition of the hedgehog pathway in advanced basal cell carcinoma. N Engl J Med. 2009;361:1164–72. PubMedCrossRef Von Hoff DD, LoRusso PM, Rudin CM, Reddy JC, Yauch RL, Tibes R, et al. Inhibition of the hedgehog pathway in advanced basal cell carcinoma. N Engl J Med. 2009;361:1164–72. PubMedCrossRef
57.
Zurück zum Zitat LoRusso PM, Rudin CM, Reddy JC, Tibes R, Weiss GJ, Borad MJ, et al. Phase I trial of hedgehog pathway inhibitor vismodegib (GDC-0449) in patients with refractory, locally advanced or metastatic solid tumors. Clin Cancer Res. 2011;17:2502–11. PubMedCrossRef LoRusso PM, Rudin CM, Reddy JC, Tibes R, Weiss GJ, Borad MJ, et al. Phase I trial of hedgehog pathway inhibitor vismodegib (GDC-0449) in patients with refractory, locally advanced or metastatic solid tumors. Clin Cancer Res. 2011;17:2502–11. PubMedCrossRef
58.
Zurück zum Zitat Tang JY, Mackay-Wiggan JM, Aszterbaum M, Yauch RL, Lindgren J, Chang K, et al. Inhibiting the hedgehog pathway in patients with the basal cell nevus syndrome. N Engl J Med. 2012;366:2180–8. PubMedCrossRef Tang JY, Mackay-Wiggan JM, Aszterbaum M, Yauch RL, Lindgren J, Chang K, et al. Inhibiting the hedgehog pathway in patients with the basal cell nevus syndrome. N Engl J Med. 2012;366:2180–8. PubMedCrossRef
59.
Zurück zum Zitat Sekulic A, Migden MR, Oro AE, Dirix L, Lewis KD, Hainsworth JD, et al. Efficacy and safety of vismodegib in advanced basal cell carcinoma. N Engl J Med. 2012;366:2717–9. CrossRef Sekulic A, Migden MR, Oro AE, Dirix L, Lewis KD, Hainsworth JD, et al. Efficacy and safety of vismodegib in advanced basal cell carcinoma. N Engl J Med. 2012;366:2717–9. CrossRef
60.
Zurück zum Zitat Fellner C. Vismodegib (Erivedge) for advanced basal cell carcinoma. PT. 2012;37(12):670–82. Fellner C. Vismodegib (Erivedge) for advanced basal cell carcinoma. PT. 2012;37(12):670–82.
61.
Zurück zum Zitat Stanton BZ, Peng LF. Small molecule modulators of the sonic hedgehog signaling pathway. Mol Biosyst. 2010;6:44–54. PubMedCrossRef Stanton BZ, Peng LF. Small molecule modulators of the sonic hedgehog signaling pathway. Mol Biosyst. 2010;6:44–54. PubMedCrossRef
62.
Zurück zum Zitat Tang JY, Marghoob AA. Emerging treatments and signaling pathway inhibitors. Semin Cutan Med Surg. 2011;30(Suppl 4):14–8. CrossRef Tang JY, Marghoob AA. Emerging treatments and signaling pathway inhibitors. Semin Cutan Med Surg. 2011;30(Suppl 4):14–8. CrossRef
63.
Zurück zum Zitat Kim J, Aftab BT, Tang JY, Kim D, Lee AH, Rezaee M, et al. Itraconazole and arsenic trioxide inhibit hedgehog pathway activation and tumor growth associated with acquired resistance to smoothened antagonists. Cancer Cell. 2013;23:23–34. PubMedCrossRef Kim J, Aftab BT, Tang JY, Kim D, Lee AH, Rezaee M, et al. Itraconazole and arsenic trioxide inhibit hedgehog pathway activation and tumor growth associated with acquired resistance to smoothened antagonists. Cancer Cell. 2013;23:23–34. PubMedCrossRef
64.
Zurück zum Zitat Fu J, Rodova M, Roy SK, Sharma J, Singh KP, Srivastava RK, et al. GANT-61 inhibits pancreatic cancer stem cell growth in vitro and in NOD/SCID/IL2R gamma null mice xenograft. Cancer Lett. 2013;330:22–32. PubMedCrossRef Fu J, Rodova M, Roy SK, Sharma J, Singh KP, Srivastava RK, et al. GANT-61 inhibits pancreatic cancer stem cell growth in vitro and in NOD/SCID/IL2R gamma null mice xenograft. Cancer Lett. 2013;330:22–32. PubMedCrossRef
65.
Zurück zum Zitat Lauth M, Bergström A, Shimokawa T, Toftgård R. Inhibition of GLI mediated transcription and tumor cell growth by small molecule antagonists. Proc Natl Acad Sci U S A. 2007;104:8455–60. PubMedCrossRef Lauth M, Bergström A, Shimokawa T, Toftgård R. Inhibition of GLI mediated transcription and tumor cell growth by small molecule antagonists. Proc Natl Acad Sci U S A. 2007;104:8455–60. PubMedCrossRef
66.
Zurück zum Zitat Chenna V, Hu C, Pramanik D, Aftab BT, Karikari C, Campbell NR, et al. A polymeric nanoparticle encapsulated small molecule inhibitor of hedgehog signaling (NanoHHI) bypasses secondary mutational resistance to smoothened antagonists. Mol Cancer Ther. 2012;11:165–73. PubMedCrossRef Chenna V, Hu C, Pramanik D, Aftab BT, Karikari C, Campbell NR, et al. A polymeric nanoparticle encapsulated small molecule inhibitor of hedgehog signaling (NanoHHI) bypasses secondary mutational resistance to smoothened antagonists. Mol Cancer Ther. 2012;11:165–73. PubMedCrossRef
Metadaten
Titel
Advanced basal cell carcinoma
verfasst von
MD Uwe Wollina
MD, PhD Georgi Tchernev
Publikationsdatum
01.08.2013
Verlag
Springer Vienna
Erschienen in
Wiener Medizinische Wochenschrift / Ausgabe 15-16/2013
Print ISSN: 0043-5341
Elektronische ISSN: 1563-258X
DOI
https://doi.org/10.1007/s10354-013-0193-5